CN105380912B - 一种含有他达拉非的药物组合物 - Google Patents
一种含有他达拉非的药物组合物 Download PDFInfo
- Publication number
- CN105380912B CN105380912B CN201410442729.4A CN201410442729A CN105380912B CN 105380912 B CN105380912 B CN 105380912B CN 201410442729 A CN201410442729 A CN 201410442729A CN 105380912 B CN105380912 B CN 105380912B
- Authority
- CN
- China
- Prior art keywords
- tadalafei
- pharmaceutical composition
- composition according
- tablet
- hydroxypropylβ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 19
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 19
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 9
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical class CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 235000019441 ethanol Nutrition 0.000 claims description 27
- 239000003094 microcapsule Substances 0.000 claims description 25
- 229920002472 Starch Polymers 0.000 claims description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 19
- 235000019698 starch Nutrition 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000741 silica gel Substances 0.000 claims description 15
- 229910002027 silica gel Inorganic materials 0.000 claims description 15
- 239000008107 starch Substances 0.000 claims description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 14
- 229920003081 Povidone K 30 Polymers 0.000 claims description 14
- 238000005469 granulation Methods 0.000 claims description 14
- 230000003179 granulation Effects 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 239000011122 softwood Substances 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- -1 α hydroxypropyl beta cyclodextrins Chemical class 0.000 abstract description 10
- 238000004090 dissolution Methods 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 43
- 235000015424 sodium Nutrition 0.000 description 11
- 125000005909 ethyl alcohol group Chemical group 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 208000010228 Erectile Dysfunction Diseases 0.000 description 7
- 201000001881 impotence Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 3
- 229960000835 tadalafil Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- FPLYNRPOIZEADP-UHFFFAOYSA-N octylsilane Chemical group CCCCCCCC[SiH3] FPLYNRPOIZEADP-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000036259 sexual stimuli Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410442729.4A CN105380912B (zh) | 2014-09-03 | 2014-09-03 | 一种含有他达拉非的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410442729.4A CN105380912B (zh) | 2014-09-03 | 2014-09-03 | 一种含有他达拉非的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105380912A CN105380912A (zh) | 2016-03-09 |
CN105380912B true CN105380912B (zh) | 2018-09-11 |
Family
ID=55414094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410442729.4A Active CN105380912B (zh) | 2014-09-03 | 2014-09-03 | 一种含有他达拉非的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105380912B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111481522A (zh) * | 2020-04-07 | 2020-08-04 | 乐普制药科技有限公司 | 一种达格列净微囊化缓释片剂及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100998569A (zh) * | 2006-12-30 | 2007-07-18 | 桂林制药有限责任公司 | 一种含青蒿素或其衍生物的复方抗疟药三层片及其制备工艺 |
CN102600065A (zh) * | 2012-03-31 | 2012-07-25 | 加拿大力邦制药有限公司 | 一种氟维司群或其衍生物油性制剂及其制备方法 |
CN103070787A (zh) * | 2013-02-18 | 2013-05-01 | 上海应用技术学院 | 一种w/o型聚硅氧烷纳米乳液及其制备方法 |
CN103191075A (zh) * | 2013-04-28 | 2013-07-10 | 南京海融医药科技有限公司 | 他达拉非的口服药物制剂 |
CN103271885A (zh) * | 2013-05-23 | 2013-09-04 | 浙江华海药业股份有限公司 | 他达拉非口腔崩解片及其制备方法 |
CN103690425A (zh) * | 2013-12-12 | 2014-04-02 | 上海应用技术学院 | 一种o/w型含柠檬精油亚微米乳液及其制备方法 |
-
2014
- 2014-09-03 CN CN201410442729.4A patent/CN105380912B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100998569A (zh) * | 2006-12-30 | 2007-07-18 | 桂林制药有限责任公司 | 一种含青蒿素或其衍生物的复方抗疟药三层片及其制备工艺 |
CN102600065A (zh) * | 2012-03-31 | 2012-07-25 | 加拿大力邦制药有限公司 | 一种氟维司群或其衍生物油性制剂及其制备方法 |
CN103070787A (zh) * | 2013-02-18 | 2013-05-01 | 上海应用技术学院 | 一种w/o型聚硅氧烷纳米乳液及其制备方法 |
CN103191075A (zh) * | 2013-04-28 | 2013-07-10 | 南京海融医药科技有限公司 | 他达拉非的口服药物制剂 |
CN103271885A (zh) * | 2013-05-23 | 2013-09-04 | 浙江华海药业股份有限公司 | 他达拉非口腔崩解片及其制备方法 |
CN103690425A (zh) * | 2013-12-12 | 2014-04-02 | 上海应用技术学院 | 一种o/w型含柠檬精油亚微米乳液及其制备方法 |
Non-Patent Citations (1)
Title |
---|
茶多酚微胶囊对油脂自氧化的抑制活性;车春波;《哈尔滨商业大学学报(自然科学版)》;20100830;第26卷(第4期);第400-403页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105380912A (zh) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100536870C (zh) | 一种新复方大青叶制剂的检测方法 | |
CN104459003B (zh) | 缩泉制剂标准指纹图谱及特征图谱的构建方法及质量检测方法 | |
CN104749269B (zh) | 一种利用hplc测定阿格列汀原料药及制剂中对映异构体杂质的方法 | |
CN104306745A (zh) | 一种天麻醒脑胶囊的质量控制方法 | |
CN102879495B (zh) | 一种藏药组合物解毒胶囊及其制剂的质量检测方法 | |
CN104345111A (zh) | 一种中药组合物制剂中多种活性成分含量的测定方法 | |
CN109662950A (zh) | 一种含有盐酸达泊西汀的药物组合物 | |
CN102397342B (zh) | 一种金荞麦提取物,含其制剂及其制备方法 | |
CN101315355A (zh) | 一种康复新制剂的指纹图谱质量测定方法 | |
CN101757099A (zh) | 金茵利胆药物及其制备方法和质量控制方法 | |
CN100457159C (zh) | 治疗慢性咽喉炎的泡腾片及质量控制方法 | |
CN109864975B (zh) | 一种阿立哌唑的口腔崩解片及其制备方法 | |
CN106214656A (zh) | 一种复方甘草酸苷片的制备及质量控制检测方法 | |
CN105380912B (zh) | 一种含有他达拉非的药物组合物 | |
CN101653491A (zh) | 一种桂枝茯苓制剂的制备工艺和质量控制方法 | |
CN101647993A (zh) | 一种用于治疗流行性感冒的药物及其制备和检测方法 | |
CN101011474A (zh) | 含制草乌中药乌头碱限量检测方法 | |
CN106943356B (zh) | 一种泛昔洛韦缓释颗粒剂及其制备方法 | |
CN102293759A (zh) | 右旋布洛芬缓释片制剂及其制备方法 | |
CN102552210B (zh) | 一种恩替卡韦胶囊组合物及其制备方法 | |
CN101279055A (zh) | 参芪花粉制剂新的治疗用途及质量控制方法 | |
CN104069080B (zh) | 一种琥珀酸普芦卡必利片剂组合物 | |
CN101028474B (zh) | 一种具有壮阳益肾功能中药制剂补肾康乐的质量检测方法 | |
CN101428020A (zh) | 一种苦参素冻干粉制剂及其制备和检测方法 | |
CN1958007B (zh) | 一种治疗宫颈炎、宫颈糜烂的阴道片剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination containing tadalafil Effective date of registration: 20231226 Granted publication date: 20180911 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000149 |